We want to make Montpellier a centre of excellence and expertise in the field of Biomarkers and P6 Medicine (Personalized, Preventative, Predictive, Participatory, Patient-centred, Precision)
The challenges linked to care pathway optimization in the framework of the development of the future medicine and healthcare policies are enormous. Indeed, we must ensure the implementation of a medicine that will progressively become more predictive and personalized, from preventative measures to post-treatment follow-up. Targeted therapies are at the heart of this more efficient medicine with treatments adapted to the different subtypes of the same pathology (stratification) and also to the complexity of each individual patient (genetic, comorgidities, environmental and epigenetic features…). These advances strongly rely on biomarkers for diagnostic and prognostic approaches, and also for optimal therapeutic decision-making.
Comprehensive patient data and biomarkers are both essential not only to confirm the diagnosis, but also to determine the pathology subtypes, to make links with the disease course or the treatment response… These elements are at the basis of numerous research projects in many MUSE research fields, from basic research to the clinic.
However, for the optimal exploitation of these data, it is crucial to develop new bio-informatics and mathematical tools. Robust data analysis and interpretation will allow validating or challenging physio-pathological hypotheses. Therefore, they are a potential stimulus for new clinical, basic, and translational research.
The aim of the key initiative of MUSE (KIM) «Biomarkers & Therapy» is to strengthen the structuring of the links between clinical teams, academic research and the socio-economic world, thus allowing:
The KIM Biomarkers & Therapy relies on the MUSE community of more than 1,000 researchers, and is organized around:
MUSE research clusters
Three health institutions
Different umbrella structures
Five Laboratories of Excellence (LabEx)
Two doctoral schools
This scheme falls within one of the seven regional priority innovation objectives in Health and Medicine of the Future that are managed, in the Occitanie region, by the project officers of the economic development regional agency AD’OCC.
It is integrated in the objective of the Montpellier Capital Santé (Montpellier Health) project to develop large-scale projects and to strongly increase Montpellier Méditerranée Métropole visibility at the European scale.
Finally, it is also one of the priority axes of the Eurobiomed competitiveness cluster that has been contributing to the success and innovation in the regional health sector for more than 10 years.